Anondita Medicare profit rises to Rs 22.01 crore in H1
Key highlights
- Anondita Medicare’s consolidated profit after tax rose to Rs 22.01 crore from Rs 13.02 crore year on year.
- Revenue from operations increased to Rs 73.54 crore from Rs 54.10 crore in the September 2026 half year.
- Cash and cash equivalents were Rs 91.51 crore at September 30, 2026, compared with Rs 9.65 crore at March 31, 2026.
- Long-term and short-term borrowings totalled Rs 70.61 crore at September 30, 2026.
powered by IRIS

Anondita Medicare Limited reported unaudited consolidated profit after tax of Rs 22.01 crore for the half year ended September 30, 2026, against Rs 13.02 crore a year earlier, as revenue from operations increased to Rs 73.54 crore from Rs 54.10 crore. The consolidated accounts cover the holding company, its subsidiary and associate.
Know Anondita Medicare inside out
Results, valuation, peers and who's buying, in one view.
How did Anondita Medicare’s revenue and profit change?
Anondita Medicare’s revenue from operations rose by Rs 19.44 crore year on year to Rs 73.54 crore in the half year ended September 30, 2026. Including other income of Rs 60.48 lakh, total income reached Rs 74.15 crore, compared with Rs 54.50 crore in the corresponding half year ended September 30, 2025. Profit before tax increased to Rs 29.45 crore from Rs 17.38 crore.
Profit after tax rose by Rs 8.99 crore to Rs 22.01 crore. Of the latest profit, Rs 21.31 crore was attributable to owners of Anondita Medicare and Rs 69.78 lakh to minority interest. Basic and diluted earnings per equity share were each Rs 11.76, compared with Rs 9.08 in the September 2025 half year.
The latest period differed from the immediately preceding six months. Revenue of Rs 73.54 crore was Rs 9.78 crore below the Rs 83.32 crore reported for the half year ended March 31, 2026, but profit after tax was Rs 72.74 lakh higher than Rs 21.28 crore. Profit before tax was marginally lower than the March-half figure of Rs 29.51 crore.
What changed in Anondita Medicare’s costs and tax?
Anondita Medicare reported total expenses of Rs 44.69 crore for the September 2026 half year, compared with Rs 37.13 crore a year earlier. Total income increased by Rs 19.64 crore while expenses increased by Rs 7.56 crore, resulting in the Rs 12.08 crore rise in reported profit before tax. This comparison is based on the income-statement lines in the filing.
Cost of materials consumed increased to Rs 27.75 crore from Rs 23.53 crore, while purchases of stock-in-trade rose to Rs 12.95 crore from Rs 1.65 crore. The statement recorded a Rs 12.78 crore reduction in inventories of finished goods, work in progress and stock-in-trade, compared with a Rs 79.18 lakh reduction in the prior-year half.
Employee-benefit expense was Rs 4.61 crore against Rs 3.48 crore, finance costs were Rs 2.42 crore against Rs 1.82 crore, and depreciation and amortisation was Rs 1.42 crore against Rs 40.87 lakh. Other expenses increased to Rs 8.30 crore from Rs 7.02 crore. Current tax was Rs 7.00 crore, deferred-tax expense was Rs 44.93 lakh and tax for earlier years was Rs 59.08 lakh.
What does Anondita Medicare’s September balance sheet show?
Anondita Medicare’s consolidated balance-sheet total was Rs 351.79 crore at September 30, 2026, compared with Rs 184.83 crore at March 31, 2026. Reserves and surplus increased to Rs 221.02 crore from Rs 111.15 crore, while share capital rose to Rs 19.04 crore from Rs 18.09 crore. The September balance sheet also included Rs 7.40 crore received against share warrants.
Cash and cash equivalents stood at Rs 91.51 crore at September 30, compared with Rs 9.65 crore at March 31 and Rs 36.51 crore a year earlier. Trade receivables increased to Rs 60.02 crore from Rs 51.86 crore at March 31, while inventories rose to Rs 35.17 crore from Rs 20.75 crore. Both cash and operating working-capital balances therefore expanded during the six-month period.
Capital work in progress was Rs 74.21 crore at September 30, up from Rs 41.50 crore at March 31. Property, plant and equipment increased to Rs 52.97 crore from Rs 39.10 crore, while short-term loans and advances rose to Rs 23.57 crore from Rs 11.15 crore. Non-current investments were unchanged at Rs 3.31 crore across the two balance-sheet dates.
Got a follow-up? Ask IRIS
How did Anondita Medicare’s funding and obligations move?
Anondita Medicare reported long-term borrowings of Rs 42.73 crore at September 30, 2026, versus Rs 23.87 crore at March 31. Short-term borrowings rose to Rs 27.88 crore from Rs 9.73 crore. Combined reported borrowings consequently increased by Rs 37.01 crore to Rs 70.61 crore over the six months.
Trade payables to creditors other than micro and small enterprises were Rs 10.66 crore at September 30, compared with Rs 6.62 crore at March 31. Short-term provisions increased to Rs 13.77 crore from Rs 7.33 crore, and other current liabilities were Rs 2.95 crore against Rs 2.49 crore. These changes accompanied increases in receivables, inventories and short-term loans and advances.
The unaudited cash-flow statement reported Rs 47.94 crore of net cash used in investing activities during the September 2026 half year, compared with Rs 9.46 crore used in the September 2025 half year. The larger investing outflow coincided with increases of Rs 32.71 crore in capital work in progress and Rs 13.87 crore in property, plant and equipment from March 31, 2026.
What did the auditor and IPO filing disclose?
Jain Chopra & Company issued an unmodified limited-review conclusion dated November 14, 2026. The auditor said nothing had come to its attention indicating that the consolidated statement failed to disclose required information or contained a material misstatement. A limited review is narrower in scope than an audit and does not provide audit assurance.
The group comprises Anondita Medicare, subsidiary Anondita Pharma and Latex Limited, formerly Anondita Healthcare and Rubber Products India Limited, and associate Anondita Healthcare, a partnership firm. The review report said the consolidated results included Rs 6.33 crore of net profit after tax for the September 2026 half year relating to the subsidiary financial statement reviewed by another auditor, versus Rs 1.48 crore a year earlier.
Anondita Medicare also reported no deviation or variation in its use of initial public offering, or IPO, proceeds for the half year ended September 30, 2026. The IPO raised Rs 69.50 crore on August 28, 2025. The company said the monitoring agency, Infomerics Valuation and Rating Limited, reported no deviation or variation.
Conclusion
Anondita Medicare’s September 2026 consolidated results show higher year-on-year revenue, profit before tax and profit after tax, alongside a balance-sheet expansion to Rs 351.79 crore. Revenue rose to Rs 73.54 crore and profit after tax reached Rs 22.01 crore, while cash, receivables, inventories, fixed assets, capital work in progress and borrowings all increased from March 31, 2026.
The next disclosed development to watch is deployment of IPO proceeds towards working capital. Anondita Medicare said working-capital allocation was revised to Rs 37.78 crore from Rs 35.00 crore after revised general corporate purpose limits, and said its turnover estimate for financial year 2025-26 had been revised to approximately Rs 145 crore from Rs 100 crore due to expanded operations and higher working-capital requirements.


